Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little a...
The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025Concurrent wit...
Channel Therapeutics shares rise after announcing 10-for-1 reverse stock split and upcoming rebrand.
Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), an emerging leader in the developm...
Chromocell Therapeutics (AMEX:CHRO) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate ...
